Skip to main content

FDA May Fast-track Needed Drugs

New congressional proposals would allow drug makers to bypass traditional clinical trial requirements for drugs that address rare diseases.

Written byTia Ghose
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

FLICKR, CANDY

As part of the renewal of pharmaceutical licensing fees, Congress is considering two proposals for the US Food and Drug Administration to fast-track drugs that address rare diseases or conditions for which no approved cures exist.

Senator Kay Hagan, a democrat from North Carolina, and the Biotechnology Industry Organization have developed plans that would allow pharmaceutical companies to skip traditional clinical trial requirements for drug approval, in essence broadening the accelerated approval program used for cancer and AIDS drugs to include rare disorders. According to the proposal, drugs that may qualify would address one of 7,000 conditions that affect fewer than 200,000 people per year in the country, Bloomberg News reported. Currently, only about 360 drugs are approved for those conditions, according the National Organization ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation